Treatment with cisplatin and an egfr-inhibitor

Details Treatment with cisplatin and an egfr-inhibitor Treatment with cisplatin and an egfr-inhibitor

A - Human Necessities

61

K

A61K 33/24 (2006.01) A61K 31/4706 (2006.01) A61K 31/517 (2006.01) A61K 31/519 (2006.01) A61K 31/5377 (2006.01) A61P 35/00 (2006.01)

Patent

CA 2567852

The present invention provides a method for manufacturing a medicament for treating tumors or tumor metastases, characterized in that a therapeutically effective amount of an EGFR kinase inhibitor and cisplatin is used, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The invention also encompasses a pharmaceutical composition that is comprised of an EGFR kinase ihibitor and cisplatin combination in combination with a pharmaceutical acceptable carrier. A Preferred example of an EGFR kinase inhibitor that can be used in practicing this invention is the compound erlotinib HC1 (also known as TarcevaTM).

L'invention porte sur le procédé de fabrication d'un médicament de traitement des tumeurs et des métastases tumorales consistant en un inhibiteur de la EGFR kinase associé à de la cisplatine et s'administrant en doses à effet thérapeutiques avec ou sans agent ou traitement additionnel tels que d'autres médicaments anticancéreux ou une radiothérapie. L'invention porte également sur une préparation pharmaceutique comprenant un inhibiteur de la EGFR kinase associé à de la cisplatine, combinés à un excipient pharmacocompatible. L'exemple préféré d'inhibiteur de la EGFR kinase utilisable dans le cadre de l'invention est le composé erlotinibe HC1 (également connu sous l'appellation de Tarceva<SP>TM</SP>).

Affiliated with

Also associated with

Rating

Treatment with cisplatin and an egfr-inhibitor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment with cisplatin and an egfr-inhibitor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment with cisplatin and an egfr-inhibitor will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1674403